VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2022 | Improving the use of MRD for the prognosis and treatment of ALL

Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, briefly explains the importance of measurable residual disease (MRD) in the prognosis and treatment of patients with acute lymphoblastic leukemia (ALL), and comments on ways to improve and standardize the use of MRD in this disease. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter